Aloperine induces apoptosis and inhibits invasion in MG-63 and U2OS human osteosarcoma cells - 31/12/17
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 8 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Aloperine (ALO) is a novel type of alkaloid drug that is extracted from S. alopecuroide, and exert an anti-inflammatory, anti-allergenic, antitumor and antiviral effects. In our study, we evaluated the effects and underlying mechanisms of ALO on MG-63 and U2OS osteosarcoma (OS) cells. ALO suppressed the proliferation and clonogenecity of both cell lines in a dose- and time-dependent manner as observed by CCK-8 and clonogenic survival assays. Data of morphologic changes, DAPI assays and flow cytometry showed that ALO induced apoptosis of OS cells, and the results of western blotting and qRT-PCR indicated that ALO upregulated protein and mRNA of Bax and cleaved caspase-3, while downregulated Bcl-2. Besides, ALO inhibited the invasion of MG-63 and U2OS cells as shown by transwell invasion assay. The protein and mRNA of MMP-2 and MMP-9 were decreased with ALO treatment. ALO also downregulated the protein and mRNA expression of PI3K and p-AKT1. In conclusion, ALO induced apoptosis and inhibited invasion in MG-63 and U2OS cells, which maybe through suppression of PI3K/AKT signaling pathway.
Le texte complet de cet article est disponible en PDF.Keywords : Aloperine, Apoptosis, Invasion, MG-63, U2OS
Plan
Vol 97
P. 45-52 - janvier 2018 Retour au numéro
Article précédent
- In vitro and in vivo toxicity assessment of alginate/eudragit S 100-enclosed chitosan–calcium phosphate-loaded iron saturated bovine lactoferrin nanocapsules (Fe-bLf NCs)
- Khoo Miew Leng, Soundararajan Vijayarathna, Subramanion L. Jothy, Sreenivasan Sasidharan, Jagat R. Kanwar
- Fullerene C60 nanoparticles ameliorated cyclophosphamide-induced acute hepatotoxicity in rats
- Abd-Elraheim A. Elshater, Mohie A.M. Haridy, Muhammad M.A. Salman, Asmaa S. Fayyad, Seddik Hammad
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?